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The study of medications among paediatric patients has increased worldwide since 1997 in response 
to new legislation and regulations. In Europe since January 2007, the Regulation aims to ensure that 
medicines for use in children are of high quality, are ethically researched and authorized 
appropriately and to improve the availability of information on the use of medicines for children. 
Therefore, we are only in the process of measuring the 10-year impact on paediatric research, 
availability of authorized medicines and information on medicines. However considering the lengthy 
overall development cycle times, we will probably have to wait yet another decade, for the next big 
anniversary, to appreciate a tangible influx of new age–appropriate paediatric treatments. 
 In the meantime, young patients are and will be commonly treated with off-label or unlicensed 
drugs. Not only is their use associated with a greater risk of harm than with the use of appropriately 
licensed medicine, but also there is a lack of safe formulations in suitable doses that children are 
able and willing to take. This is especially true for neonates and infants, the most vulnerable patients 
of the paediatric subsets, who remain ‘therapeutic orphans’ despite the potential known impact on 
pharmacokinetics of maturational changes relating to changes in body composition, organ weight 
and also function, on pharmacogenetics, and on pharmacodynamics. Even excipients, which are 
never prescribed yet almost, always administered carry potential adverse effects especially in 
neonates.  
The regulatory stimulus requires companies to develop their paediatric investigation plan, discussing 
the proposed clinical trials in children of different ages and their intention for future commercial 
dosage forms. This has undeniably stimulated interest in furthering the way medicines are designed 
and made, the way they are studied in non-clinical and clinical phases.  
The intent of this special issue on Paediatric Medicine in Journal of Pharmacy and Pharmacology is to 
celebrate progress and advances around not only paediatric medicines research and development 
but also to enable better-evidenced off-label and unlicensed medicines use practices. This collective 
of Research Papers, (mini)Reviews and letters range from pharmaceutics and drug delivery, 
experimental and clinical pharmacology to biopharmaceutics and rug disposition, all dedicated to 
children care across any therapeutic area, route of administration, clinical setting and borders 
 
